
The Biosimilars Council, the leading US trade association representing manufacturers of biosimilar medicines, has applauded the bipartisan introduction of the Biosimilar Red Tape Elimination Act in the US House of Representatives.
The legislation, sponsored by Representatives August Pfluger (Republican -Texas) and Greg Landsman (Democrat -Ohio), removes the arbitrary and unscientific distinction between biosimilars and interchangeable biologics. In June, companion legislation was introduced in the Senate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze